Detection of mycobacterial pulmonary diseases via breath analysis in clinical practice

BackgroundCurrent clinical tests for mycobacterial pulmonary diseases (MPD), such as pulmonary tuberculosis (PTB) and non-tuberculous mycobacteria pulmonary diseases (NTM-PD), are inaccurate, time-consuming, sputum-dependent, and/or costly. We aimed to develop a simple, rapid and accurate breath test for screening and differential diagnosis of MPD patients in clinical settings. MethodsExhaled breath samples were collected from 93 PTB, 68 NTM-PD and 4 PTB&NTM-PD patients, 93 patients with other pulmonary diseases (OPD) and 181 healthy controls (HC), and tested using the online high-pressure photon ionisation time-of-flight mass spectrometer (HPPI-TOF-MS). Machine learning models were trained and blindly tested for the detection of MPD, PTB, NTM-PD, and the discrimination between PTB and NTM-PD, respectively. Diagnostic performance was evaluated by metrics of sensitivity, specificity, accuracy, and area under the receiver operating characteristic curve (AUC). ResultsThe breath PTB detection model achieved a sensitivity of 73.5%, a specificity of 85.8%, an accuracy of 82.9%, and an AUC of 0.895 in the blinded test set (n=141). The corresponding metrics for the NTM-PD detection model were 86.4%, 93.2%, 92.1% and 0.972, respectively. For distinguishing PTB from NTM-PD, the model also achieved good performance with sensitivity, specificity, accuracy, and AUC of 85.3%, 81.8%, 83.9% and 0.947, respectively. 22 potential breath biomarkers associated with MPD were putatively identified and discussed, which included 2-furanmethanol, ethanol, 2-butanone, etc. ConclusionsThe developed breathomics-based MPD detection method was demonstrated for the first time with good performance for potential screening and diagnosis of PTB and NTM-PD using a refined operating procedure on the HPPI-TOF-MS platform.